Browse by UCL people
Group by: Type | Date
Jump to: Article | Book chapter
Number of items: 14.
Article
Ahern, A;
Griffin, S;
Wheeler, G;
Sharp, S;
Aveyard, P;
Boyland, E;
Halford, J;
(2020)
The effect of referral to an open-group behavioural weight management programme on the relative risk of normoglycaemia, non-diabetic hyperglycaemia and type 2 diabetes: secondary analysis of the WRAP trial.
Diabetes, Obesity and Metabolism
, 22
(11)
pp. 2069-2076.
10.1111/dom.14123.
|
 |
|
Ahern, AL;
Wheeler, GM;
Aveyard, P;
Boyland, EJ;
Halford, JCG;
Mander, AP;
Woolston, J;
... Jebb, SA; + view all
(2017)
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial.
The Lancet
, 389
(10085)
pp. 2214-2225.
10.1016/S0140-6736(17)30647-5.
|
|
|
Burnett, T;
Mozgunov, P;
Pallmann, P;
Villar, SS;
Wheeler, GM;
Jaki, T;
(2020)
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.
BMC Medicine
, 18
, Article 352. 10.1186/s12916-020-01808-2.
|
|
|
Fennell, D;
Danson, S;
Woll, P;
Forster, M;
Talbot, D;
Child, J;
Farrelly, L;
... Wheeler, G; + view all
(2020)
Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial.
Clinical Cancer Research
, 26
(18)
pp. 4748-4755.
10.1158/1078-0432.CCR-20-1306.
|
|
Grayling, MJ;
Wheeler, GM;
(2020)
A review of available software for adaptive clinical trial design.
Clinical Trials
10.1177/1740774520906398.
(In press).
|
|
|
Pallmann, P;
Sydes, MR;
Other authors, M;
(2018)
Adaptive designs in clinical trials: why use them, and how to run and report them.
BMC Medicine
, 16
, Article 29. 10.1186/s12916-018-1017-7.
|
|
Wheeler, G;
Pallmann, P;
Wan, F;
Mander, A;
Yap, C;
Clive, S;
Hampson, L;
(2019)
Designing and evaluating dose-escalation studies made easy: the MoDEsT web app.
Clinical Trials
10.1177/1740774519890146.
(In press).
|
|
|
Wheeler, GM;
(2016)
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.
Statistical Papers
pp. 1-11.
10.1007/s00362-016-0790-7.
|
|
Wheeler, GM;
Mander, A;
Bedding, A;
Brock, K;
Cornelius, V;
Grieve, A;
Jaki, T;
... Bond, S; + view all
(2019)
How to design a dose-finding study using the Continual Reassessment Method.
BMC Medical Research Methodology
, 19
, Article 18. 10.1186/s12874-018-0638-z.
|
|
|
Wheeler, GM;
Sweeting, M;
Mander, A;
(2019)
A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data.
Journal of the Royal Statistical Society: Series C (Applied Statistics)
, 68
(2)
pp. 309-329.
10.1111/rssc.12323.
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
(2017)
Toxicity-dependent feasibility bounds for the Escalation with Overdose Control approach in phase I cancer trials.
Statistics in Medicine
, 36
(16)
pp. 2499-2513.
10.1002/sim.7280.
|
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
(2016)
AplusB: A Web Application for Investigating A plus B Designs for Phase I Cancer Clinical Trials.
PLOS ONE
, 11
(7)
, Article e0159026. 10.1371/journal.pone.0159026.
|
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
Lee, SM;
Cheung, YKK;
(2017)
Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.
Statistics in Medicine
, 36
(2)
pp. 225-241.
10.1002/sim.6912.
|
|
Book chapter
|
Wheeler, GM;
Mander, A;
Yap, C;
(2018)
Practical implementation of dose-response adaptive trials.
In:
Wiley Statsref: Statistics Reference Online.
Wiley: Hoboken, NJ, USA.
|
